https://www.selleckchem.com/products/Ilginatinib-hydrochloride.html 06 per year, 95%CI =1.03-1.10) compared to TT, even for prolonged (>3weeks) MV (38.1%). Higher risk-adjusted mortality was associated with longer duration of MV and after 9days of MV with retention of ETT compared with TT - average (mortality) treatment effect 12.6% (95%CI =10.7-14.5). The latter was not significant after 30days of MV. The safety of ETT compared with TT beyond short-term MV (≤9-days) is uncertain and requires prospective evaluation with additional data. The safety of ETT compared with TT beyond short-term MV (≤9-days) is uncertain and requires prospective evaluation with additional data. Patients with tuberculosis (TB) developing acute respiratory distress syndrome (ARDS) may have a higher mortality when compared with ARDS of other infectious etiology. In this single-centre retrospective cohort study spanning 5-years (2012 to 2016), TB-ARDS patients were age and gender matched (12) with non-TB infectious ARDS and followed up until death or hospital discharge. Clinical profile, treatment and outcomes were compared using t-test and Chi-square as appropriate. Mortality predictors were explored using Conditional Poisson regression analysis and expressed as relative risk (RR) with 95% confidence interval (CI). Of the 516 ARDS patients, 74TB-ARDS and 148 non-TB infectious ARDS patients were included. Although admission APACHE-II (21.4±7.1 vs. 17.6±6.8, p<0.001), incidence of shock (36.5% vs. 19.1%, p=0.005) and mortality (59.5% vs. 29.7%, p<0.001) were significantly higher in TB-ARDS than non-TB etiology, overall ICU length of stay and nosocomial infections were similar in both groups. On regression analysis, after adjusting for confounders, TB-ARDS (RR 1.82; 95% CI 1.13-2.92) and need for inotropes (RR 3.49; 95% CI 1.44-8.46) were independently associated with death. Patients with TB-ARDS presented sicker and had higher mortality when compared with ARDS due to non-TB infectious etiology.